Thursday, June 27, 2024
9:11 AM EST – Oncolytics Biotech Inc : Today announced the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer. The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint. The Company’s proposed study will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate therapy. Oncolytics Biotech Inc (T.ONC) shares were unchanged at 1.42.
Stocks in Play: Oncolytics Biotech Inc, Thu, 27 Jun 2024 09:27:05 EST